Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC

Published Date: 26 Jun 2026

Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mental health risk persists years after cancer diagnosis

2.

Breast cancer prevention: How nurse practitioners and physician assistants can help

3.

For treatment, the majority of cancer patients choose complementary therapies.

4.

Cancer mortality continuing to decline, says report

5.

Doctors say lung cancer is still the deadliest cancer, but hope is growing


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot